翻译BY很久没念英文的散户
新闻出自：Medical Xpress-18 分钟前
MM-398 公布结果?
标题：
智擎的MM-398在ESMO公布的结果> 对肺腺癌患者能提高存活率
原文：
MM-398 added to standard treatment
shows survival benefit in mets pancreatic cancer
内文提到
这项药物结果相当令人兴奋，因为新药MM-398 搭配 5FU
能有效对抗肺腺癌，效果比单独使用 5FU 要来得好很多。
因此这项成功的结果让我们在对抗肺腺癌时，有一个更棒的选择！
Wang-Gillam said: "The results are very exciting because the trial met its
primary endpoint and found a highly statistically significant benefit of
MM-398 plus 5FU/leucovorin on overall survival and progression-free survival
compared to 5FU/leucovorin alone.
Wang-Gillam concluded: "Our results are indicative of a successful effort in
developing new drugs toward pancreatic cancer. We now have another viable
option in this devastating disease."
结论：我翻对吗？ 困惑中。。。
※ 引述《sgssgs (三花猫)》之铭言：
: http://investors.merrimackpharma.com/releasedetail.cfm?releaseid=855045
: 看了Merrimack的网站，MM-398的三期报告，详细数据
: 会在今晚11点ESMO年会发表
: 至于Merrimack的法说会是26日晚上九点，就是明天晚上
: 会报告胰脏癌的市场，何时送FDA...etc
: 送件，拿到药证，都会有权利金入帐
: 不过，他已经涨很多了